Bristol-Myers Squibb Company Ce (CELG-RI) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $0.10. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CELG-RI = $38.68 (+38618.7% from the current price, the stock appears undervalued).
Valuation: CELG-RI trades at a trailing Price-to-Earnings (P/E) of 0 (S&P 500 average ~25).
Financials: revenue is $48.2B, +1.5%/yr average growth. Net income is $7.1B, growing at -1.9%/yr. Net profit margin is 14.6% (healthy). Gross margin is 72.5% (-5.5 pp trend).
Balance sheet: total debt is $49.0B against $18.5B equity (Debt-to-Equity (D/E) ratio 2.65, leveraged). Current ratio is 1.26 (adequate). Debt-to-assets is 54.4%. Total assets: $90.0B.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 75/100 (Partial), Health 50/100 (Partial), Moat 51/100 (Partial), Future ?/100 (Fail), Income 55/100 (Partial).
